Phage Therapy (Biocontrol*): Light and Shade Visit new site : Sellanophagetherapy.blogspot.com: Mycobacterium ulcerans Agy99, complete genome

"In silico"

From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Friday, 14 October 2011

Mycobacterium ulcerans Agy99, complete genome

Mycobacterium ulcerans Agy99, complete genome

Chromosomes: genome
Plasmids: pMUM001

Genome Info:	Features:	BLAST homologs:	Links:	Review Info:
Refseq: NC_008611	Genes: 4981	COG	Genome Project	Publications: [1]
GenBank: CP000325	Protein coding: 4160	TaxMap	Refseq FTP	Refseq Status: PROVISIONAL
Length: 5,631,606 nt	Structural RNAs: 50	TaxPlot	GenBank FTP	Seq.Status: Completed
GC Content: 65%	Pseudo genes: 771	GenePlot	BLAST	Sequencing center: Institut Pasteur
% Coding: 72%	Others: 452	gMap	TraceAssembly	Completed: 2006/12/04
Topology: circular	Contigs: None		CDD	Organism Group
Molecule: DNA			Other genomes for species:

Gene Classification based on COG functional categories

Link1
Link2
Link3
Link4
Link5

E	Enterococcus faecium	Third most common cause of HCA BSI. Increasing resistance to vancomycin.
S	Staphylococcus aureus (MRSA)	Emerging resistance to current drugs and significant drug toxicities. Lack of oral agents for step-down therapy
K	Klebsiella Escherichia coli K pneumoniae	ESBL-producing organisms increasing in frequency and severity; associated with increasing mortality. K pneumoniae carbapenemases causing severe infections in LTCF. Few active agents; nothing in development
A	Acinetobacter baumannii	Increasing worldwide, recent surge reported in hospitals. Very high mortality. Carbapenem-resistant.
P	Pseudomonas aeruginosa	Increasing P. aeruginosa infections in US and worldwide. Resistant to carbapenems, quinolones, aminoglycosides
E	Enterobacter species	MDR HCA infections increasing; resistance via ESBLs, carbapenemases, and cephalosporinases

E	Enterococcus faecium
S	Staphylococcus aureus (MRSA)	+
K	Klebsiella Escherichia coli K pneumoniae
A	Acinetobacter baumannii	+
P	Pseudomonas aeruginosa	++
E	Enterobacter species

Phage Therapy (Biocontrol*): Light and Shade Visit new site : Sellanophagetherapy.blogspot.com

messaggio

New site clik on the image

"In silico"

Phage Therapy is influenced by:

Friday, 14 October 2011

Mycobacterium ulcerans Agy99, complete genome